{"id":"phenicarbazide","rwe":[],"tags":[{"label":"phenicarbazide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Common cold","category":"indication"},{"label":"Cough","category":"indication"},{"label":"Nasal congestion","category":"indication"},{"label":"Nasal discharge","category":"indication"},{"label":"Vasomotor rhinitis","category":"indication"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PHENICARBAZIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:06:06.283245+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:06:28.149408+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:06:19.753239+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PHENICARBAZIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:06:20.364650+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1593719/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:06:20.818778+00:00"}},"allNames":"carbaphen","offLabel":[],"synonyms":["phenicarbazide","2-phenylhydrazinecarboxamide","carbaphen","phenicarbazid","phenygenine","phenylsemicarbazide"],"timeline":[],"aiSummary":"Carbaphen, marketed as Phenicarbazide, is an anti-allergenic drug primarily indicated for allergic rhinitis. Its key strength lies in its mechanism of action, which effectively modulates the body's response to allergens and irritants, reducing inflammation and congestion in the nasal passages. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.","approvals":[],"brandName":"Carbaphen","ecosystem":[{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Common cold","otherDrugs":[{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"azatadine","slug":"azatadine","company":""}],"globalPrevalence":null},{"indication":"Cough","otherDrugs":[{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"benzocaine","slug":"benzocaine","company":""},{"name":"benzonatate","slug":"benzonatate","company":"Pfizer"},{"name":"bromazine","slug":"bromazine","company":"Forest Labs"}],"globalPrevalence":null},{"indication":"Nasal congestion","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Nasal discharge","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":30000000},{"indication":"Vasomotor rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"azatadine","slug":"azatadine","company":""},{"name":"azelastine","slug":"azelastine","company":"Meda Pharms"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"phenicarbazide","explanation":"","oneSentence":"","technicalDetail":"Pharmacologically, Carbaphen is believed to exert its effects through the inhibition of histamine release and the modulation of inflammatory pathways, although the exact mechanisms are not fully understood."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2128","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PHENICARBAZIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:18:53.454888","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:06:28.149831+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"phenicarbazide","indications":{"approved":[{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA"},{"name":"Common cold","source":"DrugCentral","snomedId":82272006,"regulator":"FDA"},{"name":"Cough","source":"DrugCentral","snomedId":49727002,"regulator":"FDA"},{"name":"Nasal congestion","source":"DrugCentral","snomedId":68235000,"regulator":"FDA"},{"name":"Nasal discharge","source":"DrugCentral","snomedId":64531003,"regulator":"FDA","usPrevalence":null,"globalPrevalence":30000000,"prevalenceMethod":"curated","prevalenceSource":"Influenza Other Respir Viruses, 2023 (PMID:36824394)"},{"name":"Vasomotor rhinitis","source":"DrugCentral","snomedId":8229003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"003871","UNII":"1LR2578324","CHEBI":"CHEBI:82521","INN_ID":"4169","RXNORM":"235808","UMLSCUI":"C0770986","chemblId":"CHEMBL1593719","ChEMBL_ID":"CHEMBL1593719","PUBCHEM_CID":"61002"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:06:28.149831+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}